| 05th week of 2021 patent applcation highlights part 25 |
| Patent application number | Title | Published |
|---|
| 20210032268 | NOVEL COMPOUNDS - The invention relates to compounds of Formula (I) and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by | 2021-02-04 |
| 20210032269 | STING AGONIST COMPOUNDS AND METHODS OF USE - The present disclosure relates to STING (Stimulator of Interferon Genes) agonist compounds, methods of making the compounds and their methods of use. | 2021-02-04 |
| 20210032270 | BIARYL DERIVATIVE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL APPLICATION THEREOF - Disclosed are a biaryl derivative having a structure represented by Formula (I) and inhibitory activity against PD-1/PD-L1 interaction, a preparation method thereof, and a pharmaceutical application thereof. The series of compounds of the can be widely applied to the preparation of a medicament for preventing and/or treating cancer or tumors, immune-related diseases and disorders, contagious diseases, infectious diseases or metabolic diseases that are mediated by a PD-1/PD-L1 signaling pathway, and shows promise for the development of a new generation of PD-1/PD-L1 inhibitors. | 2021-02-04 |
| 20210032271 | PYRIDINE LACTAM COMPOUNDS AND METHODS OF USE THEREOF - The invention provides compounds having the general formula I: | 2021-02-04 |
| 20210032272 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR - This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis by administering such modulators and pharmaceutical compositions, and processes for making such modulators. | 2021-02-04 |
| 20210032273 | Methods of Making Metal Halide Perovskites - Methods of making metal halide perovskites, including methods of making micro crystals of metal halide perovskites. The metal halide perovskites, including the micro crystals, may have a 0D structure. The metal halide perovskites may be a light emitting material. | 2021-02-04 |
| 20210032274 | Novel Transition Metal Compound and Method for Preparing the Same - A transition metal compound represented by Chemical Formula I and a method for preparing the same, catalyst compositions including the same, and olefin-based polymers prepared from the same are disclosed herein. The transition metal catalyst has excellent structural stability together with excellent catalytic activity and can exhibit excellent copolymerizability even at a high temperature. In an embodiment, an olefin-based polymer prepared using a catalyst composition including the transition metal compound has a density of 0.91 g/cc or less. | 2021-02-04 |
| 20210032275 | CYCLIC GERMANIUM SILYLAMIDO PRECURSORS FOR GE-CONTAINING FILM DEPOSITIONS AND METHODS OF USING THE SAME - Methods for forming a Ge-containing film on a substrate comprise the steps of introducing a vapor of a cyclic Ge(II) silylamido precursor into a reactor having the substrate disposed therein and depositing at least part of the cyclic Ge(II) silylamido precursor onto the substrate to form the Ge-containing film using a vapor deposition method. The cyclic Ge(II) silylamido precursor is [SiMe | 2021-02-04 |
| 20210032276 | NEAR-INFRARED ABSORBING COMPOSITION, NEAR-INFRARED ABSORBING FILM AND IMAGE SENSOR FOR SOLID-STATE IMAGING ELEMENTS - Provided is a near-infrared ray absorbing composition including a near-infrared absorber and a solvent, wherein the near-infrared absorber contains at least one of the following component (A) and component (B); and a compound represented by Formula (I) is contained in the component (A) or component (B) in the range of 0.001 to 10% by mass based on the total mass of the near-infrared ray absorbing composition, Component (A): a component composed of at least one of a compound represented by Formula (1) or Formula (2) with a compound represented by Formula (I) and a copper ion, Component (B): a component composed of a copper complex obtained by reaction of at least one of a compound represented by Formula (1) or Formula (2) with a compound represented by Formula (I) and a copper compound, | 2021-02-04 |
| 20210032277 | PROGRAMMABLE POLYMERIC DRUGS - Compounds useful as biologically active compounds are disclosed. The compounds have the following structure (I): or a stereoisomer, tautomer or salt thereof, wherein R | 2021-02-04 |
| 20210032278 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - Provided are multicyclic organic electroluminescent compounds having a ligand L | 2021-02-04 |
| 20210032279 | METHOD OF SELECTIVELY FORMING COBALT METAL LAYER BY USING COBALT COMPOUND, AND METHOD OF FABRICATING SEMICONDUCTOR DEVICE BY USING COBALT COMPOUND - A method of selectively forming a cobalt metal layer includes supplying a cobalt compound represented by Chemical Formula (1) onto a substrate that includes a wiring line of a late transition metal and an isolation film adjacent thereto, and supplying a reducing gas to selectively form a cobalt metal layer on the wiring line, | 2021-02-04 |
| 20210032280 | NICOTINAMIDE RIBOSIDE ANALOGS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF - Provided herein are compounds of Formula (I) and their salts, and compositions comprising such compounds that are useful for increasing the amount of NAD | 2021-02-04 |
| 20210032281 | SENSITIVE OLIGONUCLEOTIDE SYNTHESIS USING SULFUR-BASED FUNCTIONS AS PROTECTING GROUPS AND LINKERS - Embodiments for the synthesis of sensitive oligonucleotides as well as insensitive oligonucleotides are provided. Sulfur-based groups are used for the protection of exo-amino groups of nucleobases, phosphate groups and 2′-OH groups, and as cleavable linker for linking oligonucleotides to a support. Oligonucleotide syntheses are achieved under typical conditions using phosphoramidite chemistry with important modifications. To prevent replacing sulfur-based protecting groups by acyl groups via cap-exchange, special capping agents are used. To retain hydrophobic tag to assist RP HPLC purification, special phosphoramidites are used in the last synthetic cycle. With the sulfur-based groups for protection and linking, oligonucleotide deprotection and cleavage are achieved via oxidation followed by beta-elimination under mild conditions. Therefore, besides for insensitive oligonucleotide synthesis, the embodiments of the invention are capable for the synthesis of oligonucleotide analogs containing sensitive functional groups that cannot survive the harsh conditions used in prior art oligonucleotide synthesis technologies. | 2021-02-04 |
| 20210032282 | NUCLEIC ACID COMPLEX, METHOD FOR FORMING NUCLEIC ACID HYBRIDIZATION, PHARMACEUTICAL COMPOSITION, NUCLEIC ACID PROBE, AND COMPLEMENTARY-STRAND NUCLEIC ACID COMPLEX - A nucleic acid complex includes a single-stranded nucleic acid and a cross-linked double-stranded nucleic acid including the first nucleic acid strand linked to at least one of the 5′ end and the 3′ end of the single-stranded nucleic acid and the second nucleic acid strand including a base sequence that is completely or sufficiently complementary to the first nucleic acid strand. | 2021-02-04 |
| 20210032283 | MODIFIED OLIGONUCLEOTIDES AND METHODS FOR THEIR SYNTHESIS - Modified oligonucleotides that contain one or more of the phosphate groups substituted at phosphorus and methods for their synthesis are disclosed. | 2021-02-04 |
| 20210032284 | METHOD FOR EFFICIENTLY RECOVERING AND PURIFYING ACTIVE CRM197 FROM INSOLUBLE CRM197 PROTEIN EXPRESSED IN INCLUSION BODY - Disclosed is a method for expressing and purifying insoluble proteins of CRM197. The method includes: culturing a transformant transformed with an expression vector containing a gene encoding CRM197 protein; obtaining a culture of the transformant and disrupting the cell to recover an inclusion body; solubilizing the inclusion body; treating the solubilized inclusion body with a refolding reaction mixture and performing a refolding process; and purifying the refolded CRM197 protein by chromatography. | 2021-02-04 |
| 20210032285 | METHODS, COMPOSITIONS, AND KITS FOR TRAPPING MODIFIED BIOMOLECULES - The present disclosure provides methods, compositions, and kits for trapping functionalized biomolecules. The methods, compositions, and kits utilize a trapping material comprising a reactive carbonyl group. The trapping material is designed to react rapidly and efficiently with a functionalized biomolecule that comprises a reactive amino group, thus removing the functionalized biomolecule from solution. The trapping material is therefore effective in the purification of target molecules after labeling reactions with an excess of the functionalized biomolecule. | 2021-02-04 |
| 20210032286 | PSMA Imaging Agents - Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging. | 2021-02-04 |
| 20210032287 | PEPTIDES AND COMPOSITIONS FOR USE IN COSMETICS AND MEDICINE - The present invention relates to a family of peptides which are able to interfere in the formation of complex Munc18-Syntaxin-1 and, hence, are useful in the prevention and/or treatment of neuronal exocytosis and/or muscle contractility disorders; and to prevent, reduce and/or eliminate skin aging and/or expression signs. | 2021-02-04 |
| 20210032288 | PEPTIDES FOR CANCER TREATMENT - The invention pertains to cancer treatment or prevention field. Particularly, the invention provides peptide fragments from SLIT2 protein and their applications in inhibition of cancer growth, invasion and metastasis. | 2021-02-04 |
| 20210032289 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS - In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. | 2021-02-04 |
| 20210032290 | PEPTIDES AND NANOPARTICLES FOR INTRACELLULAR DELIVERY OF MOLECULES - The present invention pertains to peptides and peptide-containing complexes/nanoparticles that are useful for stabilizing and delivering cargo molecules such as nucleic acids. | 2021-02-04 |
| 20210032291 | Compstatin Analogs With Improved Pharmacokinetic Properties - Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs in which the N-terminus contains an added or substituted component that improves (1) the peptide's binding affinity to C3 or its fragments, (2) the peptide's solubility in aqueous liquids, (3) the peptide's plasma stability, (4) the peptide's in vivo retention and/or (5) the peptide's bioavailability, as compared with an unmodified compstatin peptide under equivalent conditions. Pharmaceutical compositions and methods of using the compounds are also disclosed. | 2021-02-04 |
| 20210032292 | Treatments for Gastrointestinal Disorders - The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein. using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor. | 2021-02-04 |
| 20210032293 | KRAS-Specific Capture Agents, Compositions, and Methods of Making and Using - Disclosed are compounds, compositions, and methods involving cyclic peptides that can bind to KRAS (G12D) oncogenic protein. For example, disclosed are cyclic peptides that selectively bind KRAS (G12D) oncogenic protein. Also disclosed are methods of inhibiting KRAS (G12D) oncogenic protein in a cancer cell expressing KRAS (G12D) oncogenic protein. In some forms, the method comprises incubating the cancer cell with any one or more of the disclosed cyclic peptides. In some forms, the method comprises bringing into contact the cancer cell with any one or more of the disclosed cyclic peptides. | 2021-02-04 |
| 20210032294 | MODIFIED PlySs2 LYSINS AND USES THEREOF - Disclosed herein are modified lysin polypeptides thereof comprising at least one amino acid substitution as compared to a wild-type PlySs2 lysin polypeptide having an amino acid sequence of SEQ ID NO: 1, wherein the at least one amino acid substitution is in the CHAP domain and/or the SH3b domain, and wherein the modified lysin polypeptide or fragment thereof inhibits the growth, tin reduces the population, or kills at least one species of Gram-positive bacteria. Further disclosed herein are compositions comprising the modified lysin polypeptides, as well as vectors comprising a nucleic acid molecule that encodes the modified lysin polypeptide. Also disclosed herein are methods of inhibiting the growth, reducing the population, or killing at least one species of Gram-positive bacteria, methods of treating a bacterial infection, and methods of augmenting the efficacy of an antibiotic or reducing the development of antibiotic resistance. | 2021-02-04 |
| 20210032295 | INSOLUBLE FUSION PROTEIN COMPRISING ANTIMICROBIAL PEPTIDE AND METHOD FOR PRODUCING ANTIMICROBIAL PEPTIDE USING SAME - Disclosed is a method of producing an antimicrobial peptide wherein an antimicrobial peptide gene is fused with a green fluorescent protein gene expressed insolubly in | 2021-02-04 |
| 20210032296 | Alkali-Tolerant Affinity Chromatography Ligands - The Sequence Listing associated with this application is provided in text form in lieu of a paper copy, and is hereby incorporated by reference into the specification. The name of the text file containing the Sequence Listing is SequenceListing.txt. The text file is 36.3 KB, and was created on Sep. 30, 2020. | 2021-02-04 |
| 20210032297 | OLIGOMERIC PARTICLE REAGENTS AND METHODS OF USE THEREOF - Provided herein are oligomeric reagents, including oligomeric reagents of streptavidin or a streptavidin mutein, compositions thereof, and methods for manufacturing oligomeric reagents, including methods for reliably manufacturing oligomeric particle reagents of a desired size. In some cases, the reagents are oligomeric particle reagents containing a plurality of binding sites for agents, and thus the one or more agents are multimerized by reversibly binding to the oligomeric particle reagent, e.g., thereby creating a multimerized oligomeric particle reagent, having stimulatory agents multimerized thereon. Also provided are methods for using the oligomeric reagents for incubation or culturing, such as to induce stimulation of expansion, activation, and/or survival, of a composition of cells such as a population of lymphocytes. In some aspects, the disclosure provides methods and reagents for the stimulation, survival, persistence, activation, or other effect of cell populations that involve binding of agents to a molecule on the cell surface. | 2021-02-04 |
| 20210032298 | COMPOSITIONS AND METHODS FOR INHIBITING DHHC-TYPE PALMITOYLTRANSFERASES FOR CANCER TREATMENT - The present invention relates to compositions and methods for inhibiting DHHC3 palmitoyltransferase for treating cancer. Described herein, are methods of inhibiting expression or activity of programmed death-ligand 1 (PD-L1) in a cell of a subject, e.g., a human subject, in need thereof are carried out by administering to the subject an effective amount of a palmitoyltransferase inhibitor, thereby inhibiting the expression or activity of PD-L1 in the subject. The palmitoyltransferase comprises an Asp-His-His-Cys motif (DHHC)-type protein. Exemplary DHHC-type proteins include DHHC3, DHHC5, DHHC7, and DHHC17. | 2021-02-04 |
| 20210032299 | GIPR-AGONIST COMPOUNDS - The present invention relates to compounds having activity at the human glucose-dependent insulinotropic polypeptide (GIP) receptor. The present invention also relates to compounds having an extended duration of action at the GIP receptor. Such compounds may be useful in the treatment of diabetes, including type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity. | 2021-02-04 |
| 20210032300 | METHODS AND MATERIALS FOR TREATING BRAIN INJURIES - This document provides methods and materials for treating brain injuries. For example, methods and materials for using nucleic acid encoding a NeuroD1 polypeptide to convert reactive astrocytes within a brain (e.g., cerebral cortex) into functional neurons (e.g., neurons that can be functionally integrated into the brain of a living mammal (e.g., a human)) are provided. | 2021-02-04 |
| 20210032301 | PEPTIDES - The present invention relates to novel peptides derived from Melanoma-associated antigen B2 (MAGEB2), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer. | 2021-02-04 |
| 20210032302 | METHOD FOR DETECTING AN ANTIGEN-SPECIFIC ANTIBODY AND REAGENT FOR USE THEREIN - A method for detecting an antigen-specific antibody detection reagent, which includes a cationized, denatured antigenic protein immobilized on a solid-phase surface of a carrier material, is provided. The cationized, denatured antigenic protein has cationized SH groups formed from reaction with a cationizing agent. The detection reagent is capable of specifically binding to an antigen-specific antibody which binds to an epitope of the antigenic protein. The method includes contacting a sample containing the antigen-specific antibody with the detection reagent to bind the antigen-specific antibody with the detection reagent. A labeled secondary antibody is then added to allow the labeled secondary antibody to bind to the antigen-specific antibody; and the detection reagent bound with the antigen-specific antibody is detected. | 2021-02-04 |
| 20210032303 | FIBROBLAST GROWTH FACTOR 1 (FGF1) MUTANT PROTEINS THAT SELECTIVELY ACTIVATE FGFR1B TO REDUCE BLOOD GLUCOSE - The present disclosure provides FGF1 mutant proteins, which selectively bind to/activate FGFR1b. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed FGF1 mutants to reduce blood glucose in a mammal and treat a metabolic disorder are provided. | 2021-02-04 |
| 20210032304 | FIBROBLAST GROWTH FACTOR ANALOGS AND USES THEREOF - Disclosed herein are peptide analogs of human FGF. These peptide analogs exhibit improved therapeutic activity and fewer side effects when used in humans. Also disclosed are pharmaceutical or cosmetic compositions comprising the FGF analogs and pharmaceutically or cosmetically acceptable carriers or excipients. Also provided are methods of treating or preventing a disease in a subject that involves administering to the subject the disclosed FGF analogs. | 2021-02-04 |
| 20210032305 | Erythropoietin and Analogs for Veterinary Use - Provided are various embodiments relating to feline erythropoietin (EPO) polypeptide analogs with one or more additional glycosylation sites and methods of producing and using the same to treat anemia in companion animals. Also provided are various embodiments relating to EPO polypeptides having a mutation in the second binding site, polypeptides comprising an extracellular domain of EPO receptor, and methods of using the same for treating polycythemia in mammals. | 2021-02-04 |
| 20210032306 | COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY - The present disclosure encompasses compositions and methods for targeted cytokine delivery. The compositions disclosed herein comprise a cytokine linked to a ligand and may improve immunotherapy by limiting side effects associated with immunotherapy. | 2021-02-04 |
| 20210032307 | CODON OPTIMIZED PRECURSOR GENE AND SIGNAL PEPTIDE GENE OF HUMAN INSULIN ANALOGUE - Provided is a nucleic acid molecule of a codon optimized precursor gene and signal peptide gene of a human insulin analogue. The nucleic acid molecule comprises a nucleic acid molecule encoding the precursor of the fusion insulin analogue and a nucleic acid molecule encoding the yeast secreting signal peptide α-factor. The nucleic acid molecule improves the expression of the precursor of the insulin analogue in | 2021-02-04 |
| 20210032308 | LFA3 VARIANTS AND COMPOSITIONS AND USES THEREOF - The invention provides LFA3 polypeptide molecules, e.g., variant LFA3 fusion polypeptide molecules. The invention includes uses, and associated methods of using the LFA3 polypeptide molecules. | 2021-02-04 |
| 20210032309 | SINGLE-CHAIN CD40-RECEPTOR AGONIST PROTEINS - Provided herein are specific CD40 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD40L-associated disease or disorder. The CD40 receptor agonist proteins provided herein comprise three soluble CD40L domains and an Fc fragment. The CD40 receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications. | 2021-02-04 |
| 20210032310 | APOM-FC FUSION PROTEINS AND USES THEREOF - Provided herein are engineered fusion proteins comprising ApoM (e.g., human or murine ApoM) fused to a constant region (Fc) of a immunoglobulin G (IgG, e.g., human IgG or murine IgG). In some embodiments, the ApoM-Fc fusion protein further comprises a signal peptide (e.g., IL-2 signal peptide) fused to the ApoM, allowing the fusion protein to be secreted once expressed recombinantly. Methods of using the ApoM-Fc fusion protein or the sponge variants in the treatment of various diseases or disorders are provided. | 2021-02-04 |
| 20210032311 | NON-HUMAN GENE-EDITED MAMMAL, PROTEIN CRUDE EXTRACT SEPARATED FROM CONNECTIVE TISSUE OF NON-HUMAN GENE-EDITED MAMMAL, METHOD FOR PROTEIN CRUDE EXTRACT AND USES OF PROTEIN CRUDE EXTRACT - A non-human gene-edited mammal, a protein crude extract isolated from a connective tissue of the non-human gene-edited mammal, a method for preparing the protein crude extract, and uses of the protein crude extract are provided. The method includes: microinjecting a deoxyribonucleic acid sequence construct (DNA construct) containing SEQ ID NO: 4 or SEQ ID NO: 5 into a rat embryo, transplanting the rat embryo into a female rat of the same species to develop into a mature rat, and isolating a protein crude extract from a connective tissue of the mature rat. The protein crude extract includes human type I collagen and a non-native chimeric protein peptide chain. | 2021-02-04 |
| 20210032312 | CD8A-Binding Fibronectin Type III Domains - Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains are useful in therapeutic and diagnostic applications. | 2021-02-04 |
| 20210032313 | KLK5 INHIBITORY PEPTIDE - Provided is a novel peptide. The peptide contains the amino acid sequence set forth in SEQ ID NO: 61 and inhibits a protease. | 2021-02-04 |
| 20210032314 | METHODS AND COMPOSITIONS FOR ALPHA-1 ANTITRYPSIN RELATED DISEASE DISORDERS - The invention relates to methods and compositions directed at obtaining a non-natively glycosylated recombinant human alpha-1 antitrypsin (A1AT) peptides that are glycosylated in a non-native configuration that confer enhanced biologic activities. | 2021-02-04 |
| 20210032315 | HUMANIZED AND DE-IMMUNIZED ANTIBODIES - The invention relates to humanized and de-immunized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (Aβ N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of monoclonal antibodies of the invention to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of Aβ N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the antibodies of the invention. | 2021-02-04 |
| 20210032316 | Inverse Agonistic Anti-US28 Antibodies - The invention relates to a novel class of antagonistic and inverse agonistic anti-US28 antibodies, more specifically to single heavy chain variable domain antibodies (VHH) and variants and modifications thereof. The invention further relates to methods for producing these antibodies and to the use of the antibodies in methods for diagnostic and therapeutic purposes, especially for treatment of an individual suffering from a CMV-positive tumor such as glioblastoma. | 2021-02-04 |
| 20210032317 | VISTA-IG FOR TREATMENT OF AUTOIMMUNE, ALLERGIC AND INFLAMMATORY DISORDERS - The present invention relates to a fusion proteins comprising regulatory T cell protein, VISTA (V-domain Immunoglobulin Suppressor of T cell Activation (PD-L3) and an immunoglobulin protein (Ig). The invention also provides the use of VISTA polypeptides, multimeric VISTA polypeptides, VISTA-conjugates (e.g., VISTA-Ig), and VISTA antagonists for the treatment of autoimmune disease, allergy, and inflammatory conditions. | 2021-02-04 |
| 20210032318 | PREVENTION AND TREATMENT OF SYNUCLEINOPATHIC AND AMYLOIDOGENIC DISEASE - The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful prophylactic and therapeutic treatment of Parkinson's disease. | 2021-02-04 |
| 20210032319 | TAU IMMUNOTHERAPY - The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration. | 2021-02-04 |
| 20210032320 | ANTI-PCNA MONOCLONAL ANTIBODIES AND USE THEREOF - The present invention provides a monoclonal antibody or an antigen-binding portion thereof having increased binding affinity to cytoplasmic PCNA and blocks its interaction with NKp44. The present invention further provides use of the antibody or an antigen-binding portion thereof in the treatment of diseases associated with elevated expression of NKp44, such as cancer. | 2021-02-04 |
| 20210032321 | COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING BMP6 - The present invention relates to antibodies and antigen-binding fragments thereof to human BMP6 and compositions and methods of use thereof. | 2021-02-04 |
| 20210032322 | COMBINED INHIBITION OF SEMAPHORIN-4D AND TGF-BETA AND COMPOSITIONS THEREFOR - Provided herein are methods for inhibiting, delaying, or reducing tumor growth and metastases of plexin-B1, plexin-B2, and/or CD72-expressing cancer cells in a subject, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) in combination with an effective amount of antibody or antigen-binding fragment thereof that inhibits TGFβ, and, optionally, at least one other immune modulating therapy. | 2021-02-04 |
| 20210032323 | Methods Of Treating Inflammation Associated Airway Diseases And Viral Infections - The present disclosure provides methods of treating a pathogen-induced lung inflammation in a subject are provided in which an anti-S100A9 antibody is administered to a subject. Methods of treating a respiratory virus infection by administering an anti-S100A9 antibody are also provided. | 2021-02-04 |
| 20210032324 | ANTIBODY MOLECULES TO A PROLIFERATION-INDUCING LIGAND (APRIL) - Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy. | 2021-02-04 |
| 20210032325 | METHODS OF TREATING ULCERATIVE COLITIS - The present invention generally relates to the treatment of ulcerative colitis with an anti-IL-23p19 antibody, in particular dosage regimens for the treatment of the disease. | 2021-02-04 |
| 20210032326 | METHODS FOR THE TREATMENT OF GOUT - Disclosed are methods for the treatment and/or prevention of gout, comprising administering to a subject an effective amount of anti-IL-1β antibody or fragment thereof. | 2021-02-04 |
| 20210032327 | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof - Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided. | 2021-02-04 |
| 20210032328 | ANTI-TIGIT ANTIBODIES AND METHODS OF USE - The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same. | 2021-02-04 |
| 20210032329 | HUMAN ANTI-SEMAPHORIN 4D ANTIBODY - Compositions and method are provided for treating diseases associated with semaphorin-4D (SEMA4D) pathology, including autoimmune diseases, inflammatory diseases, cancers, neuroinflammatory disorders and neurodegenerative diseases. | 2021-02-04 |
| 20210032330 | ANTI-TIM-3 ANTIBODIES AND USES THEREOF - Anti-TIM-3 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer, an inflammatory disease, an autoimmune disease, a metabolic disease, and/or infectious diseases. | 2021-02-04 |
| 20210032331 | ANTI-LAG 3 ANTIBODIES AND USES THEREOF - Anti-LAG-3 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer, an inflammatory disease, an autoimmune disease, type 1 diabetes, and/or infectious diseases. | 2021-02-04 |
| 20210032332 | SIGNALLING SYSTEM - The present invention provides a chimeric antigen receptor (CAR) signalling system comprising; (i) a receptor component comprising an antigen binding domain, a transmembrane domain and a first binding domain; and (ii) an intracellular signalling component comprising a signalling domain and a second binding domain which specifically binds the first binding domain of the receptor component; wherein, binding of the first and second binding domains is disrupted by the presence of an agent, such that in the absence of the agent the receptor component and the signalling component heterodimerize and binding of the antigen binding domain to antigen results in signalling through the signalling domain, whereas in the presence of the agent the receptor component and the signalling component do not heterodimerize and binding of the antigen binding domain to antigen does not result in signalling through the signalling domain. | 2021-02-04 |
| 20210032333 | Methods and Compositions for Reducing Immunogenicity By Non-Depletional B Cell Inhibitors - Disclosed herein, in one aspect, is a method of reducing immunogenicity, comprising administering to a patient receiving or having received a biological therapeutic agent, an effective amount of B cell inhibitor that is non-depletional. Related compositions are also provided. | 2021-02-04 |
| 20210032334 | METHODS FOR TREATING CANCER USING COMBINATIONS OF ANTI-BTNL2 AND IMMUNE CHECKPOINT BLOCKADE AGENTS - The present invention relates, in part, to methods of treating cancers using combinations of anti-BTNL2 and anti-immune checkpoint therapies. | 2021-02-04 |
| 20210032335 | POLYPEPTIDES AND METHODS - The invention relates to a polypeptide comprising (i) an antigen binding domain (ii) a pre-T-alpha domain ectodomain; and (iii) a trans-membrane domain. The invention also relates to nucleic acids, kits, cells, methods and uses. | 2021-02-04 |
| 20210032336 | CD83-BINDING CHIMERIC ANTIGEN RECEPTORS - Disclosed are compositions and methods for preventing graft versus host disease (GVHD) in subjects receiving donor cells. In particular, chimeric antigen receptor (CAR) polypeptides are disclosed that can be used with adoptive cell transfer suppress alloreactive donor cells. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of suppressing alloreactive donor cells in a subject receiving transplant donor cells that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs. | 2021-02-04 |
| 20210032337 | METHOD FOR EFFICIENTLY ACTIVATING AND EXPANDING T CELLS - The present invention discloses that T cells can be efficiently activated and expanded by a simple monomeric single chain bispecific antibody without using complicated beads, accessory cells, antibody-coating plates, or tetrameric antibody complex. The present invention also discloses that T cells activated and expanded by the monomeric single chain bispecific antibody can be efficiently transduced by virus. | 2021-02-04 |
| 20210032338 | MATERIALS AND METHODS FOR MODULATING T CELL MEDIATED IMMUNITY - Anti-TRGV9 antibodies or antigen binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as cancer. | 2021-02-04 |
| 20210032339 | Methods of Using Bispecific CD33 and CD3 Binding Proteins - Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33 | 2021-02-04 |
| 20210032340 | METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF BETA2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR - Disclosed are surprising new methods and kits for identifying and treating patients treatable with PS-targeting antibodies, particularly for identifying and treating cancer patients using bavituximab and bavituximab combination therapies. The methods and kits are based on the surprising finding that defined ranges of pre-treatment blood concentrations of β2-glycoprotein 1 (β2GPI), particularly functional β2GPI, act as an indicator to accurately predict patients with better treatment outcomes. | 2021-02-04 |
| 20210032341 | Antibodies to Programmed Cell Death Protein 1 - Antibodies and antigen binding fragments thereof are provided that immunospecifically bind to PD-1, preferably human or mouse PD-1, and induce or promote an immune response that activates immune cell proliferation or activity. Contrary to the existing paradigm that PD-1 exclusively promotes a suppressive immune response, the disclosed antibodies and antigen binding fragments thereof, immunospecifically bind to PD-1 and cause an activating signal to be delivered to the immune cell that activates the immune cell rather than suppressing the immune cell. In one embodiment, the disclosed antibodies and antigen binding fragments thereof specifically bind to PD-1 expressed on immune cells. The binding of the disclosed antibodies and antigen binding fragments thereof to PD-1 on immune cells causes an activating signal to be transmitted into the immune cell, for example a signal that enhances or promotes cytokine production and/or activation of immune cell proliferation. Immune cells that express PD-1, include but are not limited to B and T cells as well as myeloid-derived cells. In one embodiment, the immune cell is a T cell, preferably a CD8+ T cell. | 2021-02-04 |
| 20210032342 | ANTI-PD-1 ANTIBODIES - The present invention relates to anti-PD-1 antibodies and antigen-binding fragments, and use of these antibodies and antigen-binding fragments in the treatment of cancer or infectious disease. | 2021-02-04 |
| 20210032343 | ANTI-PD-1/ANTI-HER2 NATURAL ANTIBODY STRUCTURAL HETERODIMERIC BISPECIFIC ANTIBODY AND METHOD OF PREPARING SAME - Provided are an anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and a method of preparing the same. More particularly, provided are a highly stable heterodimeric anti-PD-1/anti-HER2 bispecific antibody having natural IgG characteristics without mismatch between a heavy chain and a light chain, and a method of preparing the same. The bispecific antibody may bind to two target molecules simultaneously and has excellent effects in treatment of a complex disease. | 2021-02-04 |
| 20210032344 | METHODS OF TREATING TUMOR - The disclosure provides a method for treating a subject afflicted with a tumor derived from a non-small cell lung cancer (NSCLC) comprising administering to the subject a therapeutically effective amount of (a) an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or antigen-binding portion thereof and (b) an anti-CTLA-4 antibody or an antigen binding portion thereof, wherein the tumor has a high tumor mutation burden (TMB) status. The TMB status can be determined by sequencing nucleic acids in the tumor and identifying a genomic alteration, e.g., a somatic nonsynonymous mutation, in the sequenced nucleic acids. | 2021-02-04 |
| 20210032345 | ANTI-PD-L1 ANTIBODIES, COMPOSITIONS AND ARTICLES OF MANUFACTURE - The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity. | 2021-02-04 |
| 20210032346 | B7-H4 ANTIBODIES AND METHODS OF USE THEREOF - Compositions and methods of use thereof for modulating B7-H4 are provided. For example, immunomodulatory agents are provided that reduce B7-H4 expression, ligand binding, crosslinking, negative signaling, or a combination thereof. Such agents can be used to increase an immune response in a subject in need thereof. Immunomodulatory agents are also provided that increase B7-H4 expression, ligand binding, crosslinking, negative signaling, or a combination thereof. Such agents can be used to reduce an immune response in a subject in need thereof. | 2021-02-04 |
| 20210032347 | ANTI-B7-H4 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF - An anti-B7-H4 antibody, an antigen-binding fragment thereof and pharmaceutical use thereof. A chimeric antibody and a humanized antibody comprising a CDR region of the anti-B7-H4 antibody, a pharmaceutical composition comprising the anti-B7-H4 antibody and the antigen-binding fragment thereof, and use thereof as an anti-cancer medicament. A humanized anti-B7-H4 antibody and use thereof in the preparation of a medicament for treating diseases or conditions mediated by B7-H4. | 2021-02-04 |
| 20210032348 | COMPOSITIONS AND METHODS FOR TARGETING AND KILLING ALPHA-V BETA-3-POSITIVE CANCER STEM CELLS (CSCS) AND TREATING DRUG RESISTANT AND METASTATIC CANCERS - In alternative embodiments, provided are compositions and methods for treating or ameliorating an advanced cancer such as a drug resistant or metastatic cancer which express αvβ3 polypeptides on their cell surfaces, or for killing Cancer Stem Cells (CSCs) which express αvβ3 polypeptides on their cell surfaces, by using human or humanized antibodies capable of specifically binding cell surface-expressed αvβ3 (avb3) polypeptides whose Fc region has a selective affinity to human FcγR1 (CD64), but not to other FcγRs, on effector cells such as macrophages, neutrophils, and dendritic cells. By administering these antibodies to an individual in need thereof, these human or humanized antibodies are capable of treating, ameliorating or slowing the development of the advanced cancer or drug resistant cancer, or a cancer caused or initiated by or sustained by an advanced cancer or drug resistant cancer cell, or a Cancer Stem Cell (CSC). In alternative embodiments, the administered human or humanized antibodies induce an antibody-dependent cell-mediated cytotoxicity (ADCC) reaction against the advanced cancer or drug resistant cancer cell, or CSC. | 2021-02-04 |
| 20210032349 | Antibodies binding to NKG2D - The present invention generally relates to antibodies that bind to NKG2D, including multispecific antigen binding molecules e.g. for activation of T cells and/or NK cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease. | 2021-02-04 |
| 20210032350 | ANTIBODIES TO GALECTIN-3 AND METHODS OF USE THEREOF - Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind the Galactin-3 (LGALS3) carbohydrate binding domain (CBD). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer. | 2021-02-04 |
| 20210032351 | EGFRVIII ANTIBODY AND CONJUGATE, AND PREPARATION METHOD AND USE THEREOF - Disclosed are an EGFRvIII antibody and a conjugate, and a preparation method and the use thereof. The antibody comprises complementarity-determining regions (CDRs) of the EGFRvIII antibody: one or more of heavy chain CDR1, heavy chain CDR2 and heavy chain CDR3, and/or one or more of light chain CDR1, light chain CDR2 and light chain CDR3, with the amino acid sequence thereof being as described in the present invention. The EGFRvIII antibody has a high affinity with the EGFRvIII protein, and can enter cells after coupling with small molecule toxins such as MMAE and has a cytotoxic killing effect on EGFRvIII positive cells. The antibody therefore can be used for preparing drugs for treating tumors and other diseases. | 2021-02-04 |
| 20210032352 | Multivalent Binding Molecules Activating WNT Signaling and Uses Thereof - Described herein are methods to affect binding by a multivalent binding molecule to a FZD receptor and a Wnt co-receptor on a cell wherein binding by the multivalent binding molecule to both FZD receptor and co-receptor on the cell activates a Wnt signaling pathway. Also described herein are multivalent binding molecules comprising a FZD receptor binding domain and a Wnt co-receptor biding domain on either end of an Fc domain that activate a Wnt signaling pathway and methods for their use. | 2021-02-04 |
| 20210032353 | DUAL-FUNCTION ANTIBODIES TARGETING VEGFR2 AND VEGFR3 - An isolated antibody, comprising heavy chain complementary determining regions CDR1, CDR2, and CDR3 from a heavy chain variable region sequence having SEQ ID NO: 1 or 3; light chain complementary determining regions CDR1, CDR2, and CDR3 from a light chain variable region sequence having SEQ ID NO: 2 or 4; wherein the antibody binds specifically to both vascular endothelial growth factor receptor-2 (VEGFR2) and vascular endothelial growth factor receptor-3 (VEGFR3). | 2021-02-04 |
| 20210032354 | METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST - Methods for treating or preventing asthma (e.g., allergic asthma, asthma associated with allergic bronchopulmonary aspergillosis (ABPA), moderate-to-severe asthma, persistent asthma or the like) and associated conditions (e.g., ABPA, ABPA comorbid with asthma, ABPA comorbid with cystic fibrosis (CF), ABPA comorbid with asthma and CF) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided. | 2021-02-04 |
| 20210032355 | Methods of Treating Cytokine Storm Infections, Including COVID-19, By Inhibiting CCR5/CCL5 (RANTES) Interaction, and Compositions for Practicing the Same - Methods of treating a subject suffering from COVID-19 are provided. Aspects of the methods including administering to the subject an effective amount of an inhibitor of CCR5/CCL5 interaction, such as a CCR5 antagonist. Also provided are methods of assessing severity of a disease involving hypercytokinemia, such as COVID-19, by determining the level of CCL5/RANTES in a subject, as well as compositions for use in such methods. | 2021-02-04 |
| 20210032356 | METHOD FOR TREATING SEIZURES - Methods for treating seizures, more particularly treating seizures associated with epilepsy. | 2021-02-04 |
| 20210032357 | CD20 BINDING MOLECULES AND USES THEREOF - This disclosure provides pentameric and hexameric CD20 binding molecules and methods of using such molecules to direct complement-mediated, T-cell-mediated, or both complement-mediated and T-cell-mediated killing of CD20-expressing cells. | 2021-02-04 |
| 20210032358 | PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTIBODIES DIRECTED AGAINST CD3 AND CD20 AND THEIR USES - The present invention relates to pharmaceutical compositions and dosage unit forms of bispecific CD3xCD20 antibodies and to routes of administration. | 2021-02-04 |
| 20210032359 | ANTIBODIES AGAINST PHOSPHORYLCHOLINE IN COMBINATION THERAPY WITH BIOLOGIC AGENTS - Antibodies against PC, PC conjugate or bioactive components and/or fragments thereof for use in combination therapy with one or more biologic agents and/or stem cells are disclosed, as well as compositions comprising the antibodies in combination with one or more biologic agents and/or stem cells. Also disclosed are PC conjugates, PC or bioactive components and/or parts/fragments thereof for use in activation immunotherapy prior to or in combination with treatment with biologic agents and/or stem cells for curing, treating, preventing, and/or reducing the risk of developing auto-immune diseases, chronic inflammatory diseases, and cancer diseases, as well as compositions comprising them in combination with biologic agents and/or stem cells. | 2021-02-04 |
| 20210032360 | ANTIBODIES AGAINST BST1 FOR PREVENTING OR TREATING MYELODYSPLASTIC SYNDROME - The present disclosure relates to methods of preventing or treating myelodysplastic syndrome (MDS) using antibodies or antigen-binding portions thereof directed against BST1. | 2021-02-04 |
| 20210032361 | ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING MAGE-A - The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention. | 2021-02-04 |
| 20210032362 | BISPECIFIC ANTIBODY WITH PROLONGED HALF-LIFE AND ENHANCED ANTI-TUMOR EFFECT - Disclosed is a PEGylated bispecific antibody, comprising (a) an antigen-binding fragment (Fab), which has a light chain variable region (VL) and a light chain constant region (CL), a heavy chain Variable region (VH) and a part of the heavy chain constant region (CH1); (b) a single domain antigen binding fragment (VHH) fused to the C-terminus of the part of the heavy chain constant region (CH1) of the antigen binding fragment (Fab), and (c) Polyethylene glycol (PEG) fused to the C-terminus of the light chain constant region (CL) of the antigen-binding fragment (Fab). The PEGylated S-Fab (PEG-S-Fab) retained the binding specificity to both tumor cells and T cells. PEG-S-Fab enhanced the plasma stability and had a 12-fold increased half-life of S-Fab. PEG-S-Fab also had more potent tumor inhibiting efficacy in xenograft mouse model. Those data suggest that PEGylation can be an effective approach to enhance anti-tumor properties of bispecific antibodies. | 2021-02-04 |
| 20210032363 | METHODS OF TREATING T CELL EXHAUSTION BY INHIBITING OR MODULATING T CELL RECEPTOR SIGNALING - The present invention relates to T cell compositions and methods of using the same in the context of therapy and treatment. In particular, the invention provides chimeric antigen receptor (CAR) T cells that are modified to maintain functionality under conditions in which unmodified CAR T cells display exhaustion. Compositions and methods disclosed herein find use in inhibiting or reversing CAR T cell exhaustion (e.g., by modulating CAR surface expression) thereby enhancing CAR T cell function. Compositions and methods of the invention fmd use in both clinical and research settings, for example, within the fields of biology, immunology, medicine, and oncology. | 2021-02-04 |
| 20210032364 | ANTIBODIES TO M(H)DM2/4 AND THEIR USE IN DIAGNOSING AND TREATING CANCER - The present invention relates to certain anti-M(H)DM2/4 antibodies or antigen-binding fragments thereof, pharmaceutical compositions comprising anti-M(H)DM2/4 antibodies or antigen-binding fragments thereof, antibody-drug conjugates comprising anti-M(H)DM2/4 antibodies or antigen-binding fragments thereof bound to a cytotoxic drug, and the use of such antibodies, fragments, compositions and conjugates for treating cancer and/or for preventing metastases. In particular, described herein are certain antibodies or antigen-binding fragments thereof that specifically bind to extracellularly accessible epitopes of M(H)DM2/4 and inhibit tumor growth in vivo, pharmaceutical compositions comprising such antibodies or fragments, antibody-drug conjugates comprising such antibodies or fragments, and the use of such antibodies, fragments, compositions and conjugates for treating cancer or for preventing metastasis. | 2021-02-04 |
| 20210032365 | ANTI-C1S ANTIBODIES AND METHODS OF USE - The invention provides anti-C1s antibodies and methods of using the same. The affinities of the antibodies to C1s depend on pH and other conditions. The invention also provides pharmaceutical formulations comprising the antibodies, and methods of treating an individual having a complement-mediated disease or disorder comprising administering the antibody to the individual. In addition, the binding affinity of the antibody at high and low pH was measured, and mice PK study was conducted on the antibodies, and pharmacokinetics parameters of the antibodies were evaluated in this application. | 2021-02-04 |
| 20210032366 | METHODS OF TREATING NEOPLASTIC ASTROCYTOMA - The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof. | 2021-02-04 |
| 20210032367 | ANTIBODIES AGAINST HUMAN CD39 AND USE THEREOF FOR INHIBITING T REGULATORY CELLS ACTIVITY - The invention relates to antibodies against human CD39 and use thereof for inhibiting T regulatory cells (Treg) activity. More particularly CD39 antibodies may be used for the treatment or prevention of cancers and infectious diseases. | 2021-02-04 |
